Imagene AI
Imagene AI develops a living intelligence engine for adaptive, insight-driven precision medicine, powered by proprietary foundation models, large language models, and biology-tuned analysis engines that continuously learn from biological and clinical data. Our OI Suite empowers biopharma and clinical teams with advanced capabilities for biomarker discovery, mechanism of action exploration, and indication expansion by deriving meaningful insights from histopathology, gene expression, mutational profiles, and clinical records. These capabilities increase predictive power, enabling insight-driven workflows that optimize trial design and improve the likelihood of success for therapies including antibody-drug conjugates (ADCs). Imagene AI is backed by leading investors including Larry Ellison.
